Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-018-04336-z http://scihub22266oqcxt.onion/10.1038/s41467-018-04336-z C5970268!5970268!29802256     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2018 ; 9 (ä): ä Nephropedia Template TP {{tp|p=29802256|t=2018. Fibrotic microtissue array to predict anti-fibrosis drug efficacy |pdf=|usr=}}{{29802256}} gab.com Text Fibrotic microtissue array to predict anti-fibrosis drug efficacy JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=29802256 #FOAvip Fibrosis is a severe health problem characterized by progressive stiffening of tissues which causes organ malfunction and failure. A major bottleneck in developing new anti-fibrosis therapies is the lack of in vitro models that recapitulate dynamic changes in tissue mechanics during fibrogenesis. Here we create membranous human lung microtissues to model key biomechanical events occurred during lung fibrogenesis including progressive stiffening and contraction of alveolar tissue, decline in alveolar tissue compliance and traction force-induced bronchial dilation. With these capabilities, we provide proof of principle for using this fibrotic tissue array for multi-parameter, phenotypic analysis of the therapeutic efficacy of two anti-fibrosis drugs recently approved by the FDA. Preventative treatments with Pirfenidone and Nintedanib reduce tissue contractility and prevent tissue stiffening and decline in tissue compliance. In a therapeutic treatment regimen, both drugs restore tissue compliance. These results highlight the pathophysiologically relevant modeling capability of our novel fibrotic microtissue system. Twit Text FOAVip Fibrotic microtissue array to predict anti-fibrosis drug efficacy ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=29802256 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29802256 #FOAvip English Wikipedia <ref>{{Cite pmid|29802256}}</ref> Fibrotic microtissue array to predict anti-fibrosis drug efficacy #MMPMID29802256 Asmani M; Velumani S; Li Y; Wawrzyniak N; Hsia I; Chen Z; Hinz B; Zhao R Nat Commun 2018[]; 9 (ä): ä PMID29802256show ga Fibrosis is a severe health problem characterized by progressive stiffening of tissues which causes organ malfunction and failure. A major bottleneck in developing new anti-fibrosis therapies is the lack of in vitro models that recapitulate dynamic changes in tissue mechanics during fibrogenesis. Here we create membranous human lung microtissues to model key biomechanical events occurred during lung fibrogenesis including progressive stiffening and contraction of alveolar tissue, decline in alveolar tissue compliance and traction force-induced bronchial dilation. With these capabilities, we provide proof of principle for using this fibrotic tissue array for multi-parameter, phenotypic analysis of the therapeutic efficacy of two anti-fibrosis drugs recently approved by the FDA. Preventative treatments with Pirfenidone and Nintedanib reduce tissue contractility and prevent tissue stiffening and decline in tissue compliance. In a therapeutic treatment regimen, both drugs restore tissue compliance. These results highlight the pathophysiologically relevant modeling capability of our novel fibrotic microtissue system. äFibrotic microtissue array to predict anti-fibrosis drug efficacy (epmc).pdf DeepDyve Pubget Overpricing